News and Announcements

Common Post Categories

ASCO 2024 Highlights


Project Code: ΤΑCL1-0496261   Project Title: INDUSTRIAL RESEARCH FOR THE DEVELOPMENT OF NIEDANIB ORAL SOLUTION Project budget 1.250.000,00 € EU funding 750.000,00 € The objective of the R&D project implemented in the framework of the action “Reform of the clawback system and offsetting it with research and investment costs” of the Recovery and Resilience Fund […..]

Read More »

Pregnancy and Hypothyroidism

Pregnancy is a stress test for the thyroid, experts tell us. That is why the 1st Health Pod episode of the year is dedicated to pregnancy, as it causes significant changes to the levels of thyroid hormones (even in women without any thyroid problems), and also to the serious effects of Hypothyroidism during pregnancy. With […..]

Read More »

FARAN Tops FortuneGreece List

According to the FortuneGreece‘s list of the 30 fastest-growing companies in Greece in 2022, “Looking at this year’s list, the pharmaceutical company FARAN SA is in first place in the general ranking with the third highest average rate of change in Earnings before Taxes – Interest and Depreciation – EBITDA (90.8%) and the fifth highest […..]

Read More »

Infertility – Miscarriage and Hypothyroidism

In the 5th pod episode, we open the file of infertility caused by Hypothyroidism by approaching the issue both sociologically and medically. The demographic in our country tends to become a scourge. According to Eurostat data, the EU fertility rate ranks Greece in the last places, while Greek women have children at a fairly old […..]

Read More »

Congenital Hypothyroidism

The 4th episode of the hit podcast, “Health Pod, Let’s Be Aware”, on Congenital Hypothyroidism (neonatal) has been uploaded to the top 3 most popular platforms. Despite the Pandemic, we continue our travels. This time, we travel in the uncharted – for many – waters of Congenital Hypothyroidism, which is the most frequent cause of […..]

Read More »

Interview of Faran President

The historic pharmaceutical company FARAN is one of the fastest growing companies in the industry, recording an impressive increase in turnover, as Marios Katsikas, President & CEO of FARAN, tells us, answering the first question about the company’s course: In 2022, we are running with a 30% increase, which is impressive, but it becomes even […..]

Read More »

Menopause and Hypothyroidism

The 3rd episode of the hit podcast, “Health Pod, Let’s Be Aware” on Menopause and Hypothyroidism has been uploaded to all platforms. In this episode, we dive into the bottom of the infinite female existence and come face to face with the monster of Menopause and Hypothyroidism. What happens when they coexist? How much does […..]

Read More »

Faran S.A. and Quantum Genomics

On June 30, 2021, the Greek pharmaceutical company Faran has proceeded to an exclusive collaboration with the biopharmaceutical company Quantum Genomics, for the development and distribution of the innovative pharmaceutical product Firibastat for the treatment of resistant hypertension and heart failure. This is a significant investment by Faran in the research and development of an […..]

Read More »

Faran S.A. and STADA Arzneimittel AG

FARAN S.A. and STADA Arzneimittel AG, are pleased to announce the beginning of their cooperation in the field of Osteoporosis. More specifically, in the context of the cooperation with STADA Arzneimittel AG, FARAN undertakes the promotion and distribution in Greek market of Movymia, STADA’s first first bio-similar Teriparatide. Movymia is indicated for the treatment of […..]

Read More »